Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Rocket Pharmaceuticals Inc (NQ: RCKT )

16.98 +0.33 (+1.98%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rocket Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 7 Next >
Better Gene Editing Stock: Intellia Therapeutics vs. Rocket Pharmaceuticals
Rocket could launch its medicines sooner, but Intellia is aiming for larger markets. 
Via The Motley Fool
Rocket Pharmaceuticals Stock Is Blasting Off, but Here's Why You Should Tread Carefully
Its near-term risks are subtle but bigger than their flying stock price might indicate. 
Via The Motley Fool
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet
Investors are on the hunt for undervalued, under followed and emerging stocks. Retail traders have countless methods at their disposal to uncover new information. For some, this may be overwhelming. 
Via Benzinga
Dow Turns Lower; KULR Technology Group Shares Plummet
U.S. stocks traded mixed toward the end of trading, with the Dow Jones falling 100 points on Wednesday. The Dow traded down 0.29% to 34,545.66 while the NASDAQ rose 0.22% to 13,803.43. The S&P 500,... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Rocket Pharmaceuticals (RCKT) Stock Up 35% Today?
With Rocket Pharmaceuticals reaching a Phase II agreement with the FDA, RCKT stock soared, though some concerns linger. 
Via InvestorPlace
Exposures Product Safety
Rocket Pharmaceuticals Inc. (NASDAQ: RCKT) Near the Top of Equities by Percentage Gain on 9/13
Via Investor Brand Network
Analyst Expectations for Rocket Pharmaceuticals's Future
Via Benzinga
What 5 Analyst Ratings Have To Say About Rocket Pharmaceuticals
Via Benzinga
Why Eiger BioPharmaceuticals Shares Are Trading Lower By 52%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Avalo Therapeutics, Inc. (NASDAQ: AVTX) shares surged 68% to $0.2075. Avalo Therapeutics, on Sept 12, got notice from the Nasdaq as of Sept 11 the company’s securities had closing bid price of... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Dow Gains 50 Points; US Crude Oil Inventories Rise
U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 50 points on Wednesday. The Dow traded up 0.16% to 34,701.06 while the NASDAQ rose 0.44% to 13,834.85. The S&P 500,... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Expert Ratings for Rocket Pharmaceuticals
Via Benzinga
Why Shares of Rocket Pharmaceuticals Are Taking Off on Wednesday
The late-stage pharmaceutical company said it had reached an agreement with the Food and Drug Administration regarding a phase 2 trial for a Danon disease therapy. 
Via The Motley Fool
What's Going On With Gene Therapy-Focused Rocket Pharmaceuticals Stock Today?
On Tuesday, Rocket Pharmaceuticals Inc (NASDAQ: RCKT) announced that alignment has been reached with the FDA on the global Phase 2 pivotal trial of RP-A501  
Via Benzinga
Exposures Product Safety
Moderna, REV Group, Rocket Pharmaceuticals And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded mixed, with the Dow Jones gaining around 10 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
GoDaddy To Rally Around 44%? Here Are 10 Other Analyst Forecasts For Wednesday
Needham cut the price target for Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) from $60 to $53. Needham analyst Gil Blum maintained a Buy rating. Rocket Pharmaceuticals shares rose 24.3% to $19.00 in... 
Via Benzinga
Why Mainz Biomed Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket
Gainers Avalo Therapeutics, Inc. (NASDAQ: AVTX) shares rose 38.7% to $0.1713 in pre-market trading. Shares of Avalo Therapeutics jumped over 45% on Tuesday after the company agreed to divest AVTX-800... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time for another dive into the biggest pre-market stock movers as we check out all the shares worth watching on Wednesday! 
Via InvestorPlace
Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock
From Rocket Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Reaches FDA Alignment on Pivotal Phase 2 Trial Design for RP-A501 in Danon Disease
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Progress
From Rocket Pharmaceuticals, Inc.
Via Business Wire
3 Small-Cap Stocks You Can’t Ignore Now
Finding promising small-cap stocks can be like a winning lottery ticket, providing years of steady and increasing gains to investors. 
Via InvestorPlace
Rocket Pharmaceuticals Inc. (NASDAQ: RCKT) Sets New 52-Week High in Friday Session
Via Investor Brand Network
Rocket Pharmaceuticals Receives FDA Fast Track and Orphan Drug Designations for RP-A601 Gene Therapy for PKP2 Arrhythmogenic Cardiomyopathy (ACM)
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Receives European Medicines Agency (EMA) Priority Medicines (PRIME) Designation for RP-A501 Gene Therapy for Danon Disease
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-L301 Gene Therapy for Pyruvate Kinase Deficiency (PKD)
From Rocket Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.